Table 2 Dictionary of items to be extracted from included studies, with description and rationale
Data item | Description and rationale |
|---|---|
Study characteristics | |
 Study ID | Unique identifier for each study retrieved. |
 Trial acronym/first author | Either the trial acronym (if applicable, e.g. HOPE, VALUE) or first author of the primary study report if not (e.g. Smith AB et al.). |
 Year | Year of primary study publication. |
 Study design | Placebo-controlled, active comparator-controlled or PROBE design. |
 Duration of follow-up | Time period (in months) over which participants underwent follow-up |
 Age | Mean age of all patients included in analysis. |
 Sex | Number (%) of male study participants. |
 Hypertension | Number (%) of study participants with hypertension. |
 Heart failure | Number (%) of study participants with heart failure. |
 Diabetes | Number (%) of study participants with diabetes. |
 Ischaemic heart disease | Number (%) of study participants with ischaemic heart disease. |
 Loss to follow-up | Number (%) of study participants lost to follow-up |
 Revascularisation | Number (%) of study participants that underwent invasive coronary revascularisation |
 Concomitant drug therapy | Number (%) of study participants receiving other cardiovascular agents (β-blockers, calcium channel blockers, etc.) |
Exposures and outcomes for each group | |
 Group class | Class of agent in the intervention and comparator arms (i.e. ACEi or ARB and placebo or active comparator). |
 Group agent | Identity of agent given to participants randomised to the intervention and comparator arms |
 n in group | Number in intervention and comparator arms (included in final analysis) |
 Baseline SBP | Baseline systolic blood pressure (mmHg) in each group. If multiple are provided (e.g. sitting, ambulatory, supine, etc.) sitting/clinic measurement will be used. |
 Follow-up SBP | Systolic blood pressure measured during follow-up in each group (mmHg). Any SBP measured at ‘steady-state’ during follow-up, or SBP averaged across visits may be included. If serial measurements are reported, the last measurement will be extracted. SBP after the first-dose of the medication will not be included. |
 Within-group difference in SBP | The within-group change in SBP from baseline to follow-up either directly reported or calculated as per Fig. 2. Directly reported differences will supersede calculated values. |
 Between-group difference in SBP | The between-group difference in SBP change, either directly reported or calculated as per Fig. 2. Directly-reported differences will supersede calculated values. |
 Baseline DBP | Baseline diastolic blood pressure (mm Hg) in each group. If multiple are provided (e.g. sitting, ambulatory, supine, etc.) sitting/clinic measurement will be used. |
 Follow-up DBP | Diastolic blood pressure measured during follow-up in each group (mm Hg). Any DBP measured at ‘steady-state’ during follow-up, or SBP averaged across visits may be included. If serial measurements are reported, the last measurement will be extracted. DBP after the first-dose of the medication will not be included. |
 Within-group difference in DBP | The within-group change in DBP from baseline to follow-up either directly reported or calculated as per Fig. 2. Directly-reported differences will supersede calculated values. |
 Between-group difference in DBP | The between-group difference in DBP change either directly reported or calculated as per Fig. 2. Directly reported differences will supersede calculated values. |
 All-cause mortality | The total number of deaths, of any cause, that occur in each group during follow-up. If the denominator is different to ‘n in group’, this must be specified. |
 Cardiovascular mortality | The number of cardiovascular deaths that occur in each group during follow-up. If the denominator is different to ‘n in group’, this must be specified. |
 Definition of cardiovascular mortality | Study definition of cardiovascular mortality, as per Table 2, below. |
 Myocardial infarction | The number of myocardial infarctions that occur in each group during follow-up. If the denominator is different to ‘n in group’, this must be specified. |
 Definition of myocardial infarction | Study definition of cardiovascular mortality, as per Table 2, below. |
 Stroke | The number of strokes that occur in each group during follow-up. If the denominator is different to ‘n in group’, this must be specified. |
 Definition of stroke | Study definition of stroke, as per Table 2, below. |